19.00
0.00 (0.00%)
| Penutupan Terdahulu | 19.00 |
| Buka | 19.00 |
| Purata Dagangan (3B) | 11,059 |
| Modal Pasaran | 1,772,007,040 |
| Harga / Jualan (P/S) | 19.87 |
| Harga / Buku (P/B) | 9.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 19 Aug 2026 |
| Margin Keuntungan | -41.34% |
| Margin Operasi (TTM) | -361.23% |
| EPS Cair (TTM) | -0.740 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 97.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 608.58% |
| Nisbah Semasa (MRQ) | 1.26 |
| Aliran Tunai Operasi (OCF TTM) | -111.36 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -81.25 M |
| Pulangan Atas Aset (ROA TTM) | -9.25% |
| Pulangan Atas Ekuiti (ROE TTM) | -235.32% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Ascentage Pharma Group Internat | Bercampur | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.00 |
|
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Institusi | 0.27% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |